Aligos Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ALGS$2.57-34.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Revenue from collaborations	$—	$19	$—	$311
Revenue from customers	741	1,250	2,017	3,005
Operating expenses:
Research and development	23,937	16,774	52,415	54,238
General and administrative	5,165	4,626	15,773	17,669
Total operating expenses	29,102	21,400	68,188	71,907
Loss from operations	(28,361)	(20,131)	(66,171)	(68,591)
Interest and other income, net	1,085	1,068	3,172	3,833
Change in fair value of 2023 common warrants	(4,205)	(105)	58,971	16,001
Loss before income tax	(31,481)	(19,168)	(4,028)	(48,757)
Income tax provision	(56)	(91)	(284)	(304)
Net loss	(31,537)	(19,259)	(4,312)	(49,061)
Other comprehensive gain:
Unrealized gain on available-for-sale securities	35	83	4	32
Other comprehensive gain	35	83	4	32
Comprehensive loss	$(31,502)	$(19,176)	$(4,308)	$(49,029)
Net loss per share, basic and diluted	$(3.04)	$(3.07)	$(0.44)	$(7.84)
Weighted average shares of common stock, basic and diluted	10,369,535	6,272,291	9,716,895	6,258,706

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.